Who
Jonathan McNeill
President and COO
Company insider
Files Form 4 as: President and COO, Crescent Biopharma; Chief Business Officer, Dyne Therapeutics.
In numbers
- Trades disclosed
- 76
- Buys
- 0
- Sells
- 28
- Bought
- $0
- Sold
- $6.5M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 Sep 2020
- Last trade
- 18 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $64K3,839 at $16.71 | filing |
| 18 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $64K3,839 at $16.71 | filing |
| 16 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $13K731 at $17.90 | filing |
| 16 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $13K731 at $17.90 | filing |
| 22 Jun 2026filed 23 Jun 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $370K20,549 at $17.99 | filing |
| 22 Jun 2026filed 23 Jun 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $370K20,549 at $17.99 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,029 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | —19,507 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | —6,000 | filing |
| 8 Dec 2025filed 10 Dec 2025 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —172,836 at $0.00 | filing |
| 19 Aug 2024filed 20 Aug 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K2,400 at $45.01 | filing |
| 19 Aug 2024filed 20 Aug 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K305 at $46.00 | filing |
| 11 Jun 2024filed 11 Jun 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K1,823 at $31.34 | filing |
| 16 May 2024filed 17 May 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $64K2,279 at $28.20 | filing |
| 16 May 2024filed 17 May 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K495 at $28.59 | filing |
| 11 Mar 2024filed 13 Mar 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,825 at $0.00 | filing |
| 11 Mar 2024filed 13 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code M | $99K17,825 at $5.54 | filing |
| 11 Mar 2024filed 13 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $454K17,825 at $25.48 | filing |
| 11 Mar 2024filed 13 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $46K1,776 at $25.71 | filing |
| 8 Mar 2024filed 13 Mar 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —86,159 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.